返回期刊详情

Drug Safety

IF3.8

论文数7163

被引数7120

期刊论文 7163

发表时间

Correction: Medications and Glucose-6-Phosphate Dehydrogenase Deficiency 更正：药物与葡萄糖-6-磷酸脱氢酶缺乏症

Drug Safety

IF3.8

2026-10-29

PREAI

Ilan Youngster; Lidia Arcavi; Renata Schechmaster; Yulia Akayzen; Hen Popilski; Janna Shimonov; Svetlana Beig; Matitiahu Berkovitch

Disproportionality Analysis Signal Detection Using the New ‘Information Component–Bicluster–Bayesian Hierarchical Model’利用新的“信息成分-双聚类-贝叶斯分层模型”进行不成比例分析信号检测

Drug Safety

IF3.8

2026-10-29

OAAI

Hannah Johnson; Maria Loane; Helen Dolk; Jorieke E. H. Bergman; Christine Damase-Michel; Joanne Given; Hedvig Nordeng; Iain Carey; Stephen J. W. Evans; Joan Morris

Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal 药物警戒案例识别框架的构建：并非所有报告都同等重要

Drug Safety

IF3.8

2026-10-23

OAAI

Michele Fusaroli; Joana Félix China; D. Sartori; Valentina Giunchi; Linda Härmark; Joep Scholl; Florence van Hunsel; G. Niklas Norén; Johan Ellenius

EudraScore: Modification of the Vigi4Eudra-score for the Assessment of the Completeness of Adverse Drug Reaction Reports in EudraVigilance EudraScore：用于评估EudraVigilance中不良反应报告完整性的Vigi4Eudra-score修改版

Drug Safety

IF3.8

2026-10-21

OAAI

Diana Dubrall; Patrick Christ; Dennis Lex; Robert Hoffmann; Thomas Grüger; Matthias Schmid; Bernhardt Sachs

Strengthening Signal Detection by Proactive Adverse Event Case Identification in Electronic Health Records Using a Text-Mining Tool 利用文本挖掘工具在电子健康记录中通过主动不良事件病例识别来增强信号检测

Drug Safety

IF3.8

2026-10-20

PREAI

Gabriëlla von Kreijfelt; Juliëtte Zwaveling; Jette A. van Lint; Loes E. Visser; Agnes C. Kant

Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance 重新评估Fezolinetant的肿瘤信号：监管推断、机制合理性及主动药物警戒的必要性

Drug Safety

IF3.8

2026-10-14

PREAI

Glen Clack; Jennifer Renwick

Current Pharmacovigilance Outsourcing Practices in Arab Countries 阿拉伯国家当前的药物警戒外包实践

Drug Safety

IF3.8

2026-10-14

PREAI

Ibrahim Abdeldayem; Thamir M Alshammari; Karine Palin

Disproportionality Analysis of FAERS Data Divergence and a Systematic Review of Comparative Safety Studies: Lessons Learned from the Example of Ranitidine and Cancer Risk FAERS数据分歧的不成比例性分析及比较安全性研究的系统综述：从雷尼替丁和癌症风险案例中汲取的教训

Drug Safety

IF3.8

2026-10-10

PREAI

Mahesh Rathod; Maheshwari Kadari; Haripriya R. Mohan; Ruby Kasana; Mounika Katravath; Masao Iwagami; Krishna Undela

Switching Patterns of Oral Retinoids to Alternative Medications: An Interrupted Time-Series Analysis of Four European Countries 口服维A酸类药物转换为替代药物的转换模式：基于四个欧洲国家的中断时间序列分析

Drug Safety

IF3.8

2026-10-08

OAAI

Judit Riera-Arnau; Shahab Abtahi; Mònica Sabaté Gallego; Elena Ballarín; Magdalena Gamba; Romin Pajouheshnia; Vjola Hoxhaj; Ema Alsina; Mar Martin-Perez; Patricia Garcia-Poza; Ana Llorente-Garcia; Diana Gonzalez-Bermejo; Gabriel Sanfélix-Gimeno; Clara Rodríguez-Bernal; Salvador Peiró; Aníbal García-Sempere; Francisco Sánchez-Sáez; Valentina Ientile; Ylenia Ingrasciotta; Claudio Guarneri; Matilde Tanaglia; Michele Tari; Eline Houben; Rosa Gini; Giuseppe Roberto; Claudia Bartolini; Olga Paoletti; Giorgio Limoncella; Anna Girardi; Giulia Hyeraci; Sarah Brøgger Kristiansen; Olaf Klungel; Miriam Sturkenboom; Carlos E. Durán

Hierarchical Algorithms for Constructing Mother–Father–Infant Linkages Under Modern Privacy Constraints 在现代隐私约束下构建母亲-父亲-婴儿关联的分层算法

Drug Safety

IF3.8

2026-10-07

PREAI

Brian Meng-Hsun Li; Michael Chun-Yuan Cheng; Edward Chia-Cheng Lai

Safety Monitoring of COVID-19 Vaccines in the Vaccine Adverse Event Reporting System (VAERS): United States, August 22, 2024–July 4, 2025 COVID-19疫苗在疫苗不良事件报告系统(VAERS)中的安全性监测：美国，2024年8月22日–2025年7月4日

Drug Safety

IF3.8

2026-10-03

PREAI

Brittney Romanson; Pedro L. Moro; Penelope Strid; Anne Hause; Erin Stroud; Paige L. Marquez; Bicheng Zhang; Carol Ennulat; Hannah Brown; John R. Su

Consumer Views on the Role of the Natural Health Products (NHPs) Industry in Pharmacovigilance for NHPs: A Qualitative Study in New Zealand 消费者对天然健康产品（NHPs）行业在NHPs药物警戒中作用的看法：一项在新西兰进行的定性研究

Drug Safety

IF3.8

2026-10-02

OAAI

Xin Yi Lim; Shane Scahill; Sanyogita Ram; Joanne Barnes

The Value of Time-to-Onset for Signal Validation: Experience from the Reporting of COVID-19 Vaccines and Glomerular Diseases in VigiBase 时滞对于信号验证的价值：来自VigiBase中COVID-19疫苗和肾小球疾病报告的经验

Drug Safety

IF3.8

2026-10-01

OAAI

Annette Rudolph; Monica Tarapues; Oskar Gauffin; Qun-Ying Yue

Drug Brand Switching: A Regulatory Perspective 药物品牌转换：监管视角

Drug Safety

IF3.8

2026-10-01

OAAI

Ping Siu Kee; Paul K. L. Chin; Michael Tatley; Rhiannon Braund; Martin A. Kennedy; Simran D. S. Maggo

Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis PCSK9抑制剂相关不良事件的信号检测：一项全国性序列对称和全球联合不成比例性分析

Drug Safety

IF3.8

2026-09-22

PREAI

Thibault Viguier; Julien Bezin; Alex Hlavaty; Charles Khouri; Antoine Pariente

The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update WHO-ISoP 药物警戒课程：2026 年更新

Drug Safety

IF3.8

2026-09-20

OAAI

Jürgen Beckmann; Marco Tuccori; Priya Bahri; Francesco Salvo; Mónica Tarapués; Manal M. Younus; Hussain Al Ramimmy; Mayada Alkhakany; Thamir Alshammari; Beate Aurich; Nicole Baker; Madhava Balakrishnan; Ghita Benabdallah; Pernette Bourdillon Esteve; Ian Boyd; Siva Kumar Buddha; Gianmario Candore; Emiliano Cappello; Angela Caro-Rojas; Rebecca Chandler; Jerin Jose Cherian; Karen Cohen; Salvatore Crisafulli; Shelley Deeks; Jean-Christophe Delumeau; Moin Don; Joan Dsouza; Ernest D. Dzidzornu; Brian D. Edwards; I. Ralph Edwards; Jefman Efendi Marzuki HY; Albert Figueras; Mohammed I. Fouda; Ayako Fukushima; Giovanni Furlan; Georgy Genov; Gloria Giraldo; Michael Gold; Tarek Hammad; Kenneth Hartigan-Go; Maria Teresa Herdeiro; Richard Hill; Noha Iessa; Katarina Ilic; Sujeet Jain; EunMi Kim; Larissa Kopp; Veronique Kugener; Smaragda Lamprianou; Navinisha Lee; Marie Lindquist; Michaela Lucas; Viola Macolic Sarinic; Ishak Mansi; Ushma C. Mehta; Johanna C. Meyer; Joseph Mitchell; Maryam Naeem; Comfort Ogar; Ladi Owolabi; Jayesh Pandit; Lembit Rägo; Emanuel Raschi; Hadir Rostom; Mulugeta Russom; George T. Sabblah; Maribel Salas; Souad Skalli; Fumihito Takanashi; Michael Tatley; Gianluca Trifiro; Claudia Vaca; Florence van Hunsel; Eugène van Puijenbroek; Jessica Liliana Vargas-Neri; Ryan J. Walker; Xinyu Weng; Ian C. K. Wong; Qun-Ying Yue; Li Zhang; Omar Aimer; Shanthi N. Pal

A Text-Mining Algorithm for Identifying Drug Pairs Potentially Involved in Prescribing Cascades: Development and Internal Validation Within the Prescribing Inappropriateness Assessment (PINA) Digital Tool 文本挖掘算法用于识别可能涉及处方级联的药物组合：Prescribing Inappropriateness Assessment (PINA) 数字工具中的开发与内部验证

Drug Safety

IF3.8

2026-09-19

OAAI

Massimo Carollo; Anna Forti; Salvatore Crisafulli; Luca L’Abbate; Irene Cristini; Federica Soardo; Marilisa Giustina Stano; David Bellantuono; Davide Benetti; Riccardo Lora; Gianluca Trifirò

The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy 失比例性分析的陷阱：对其相互交织复杂性的见解及前端缓解策略

Drug Safety

IF3.8

2026-09-17

PREAI

Manfred Hauben; Rave Harpaz; Robert Weber

Authors’ Reply to John Diaz-Decaro’s comment on: “Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness”作者对John Diaz-Decaro关于“猴痘疫苗的母婴使用：安全性与有效性的实时系统综述和荟萃分析”的评论的回复

Drug Safety

IF3.8

2026-09-17

PREAI

Agustín Ciapponi; Jamile Ballivian; Mabel Berrueta; Juan M. Sambade; Noelia Castellana; Ariel Bardach; Martin Brizuela; Julieta Caravario; Daniel Comande; Esteban Couto; Agustina Mazzoni; Edward Parker; Florencia Salva; Katharina Stegelmann; Xu Xiong; Andy Stergachis; Flor M. Munoz; Pierre Buekens

Interpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation 解读自发报告系统中的正向和反向差异性信号：一种具有方向感知评估的声明强度框架

Drug Safety

IF3.8

2026-09-17

OAAI

Yoshihiro Uesawa